Oral Mucositis in Head and Neck Cancer or Targeted Therapies

Conclusion

Palifermin appears to reduce the frequency of mucositis in patients treated for head and neck cancer, but its place in therapy has not been determined. Although the oral complications of targeted therapies are clinically distinct from those of conventional cytotoxic therapy, the literature recommends similar palliative management strategies for both.